Connor Clark & Lunn Investment Management Ltd. Grows Position in Emergent BioSolutions Inc. (NYSE:EBS)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 8.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 902,332 shares of the biopharmaceutical company's stock after purchasing an additional 69,157 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 1.67% of Emergent BioSolutions worth $8,626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EBS. SBI Securities Co. Ltd. purchased a new position in Emergent BioSolutions in the fourth quarter valued at $63,000. Stifel Financial Corp purchased a new position in Emergent BioSolutions in the third quarter valued at $96,000. E Fund Management Co. Ltd. purchased a new position in Emergent BioSolutions in the fourth quarter valued at $98,000. FORA Capital LLC purchased a new position in Emergent BioSolutions in the third quarter valued at $103,000. Finally, Landscape Capital Management L.L.C. purchased a new position in Emergent BioSolutions in the third quarter valued at $141,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. StockNews.com cut shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, March 4th.

Remove Ads

Insider Activity at Emergent BioSolutions

In related news, Director Neal Franklin Fowler sold 35,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the sale, the director now owns 101,100 shares in the company, valued at $589,413. This trade represents a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.20% of the company's stock.

Emergent BioSolutions Stock Up 2.3 %

Shares of NYSE EBS traded up $0.13 during mid-day trading on Wednesday, reaching $5.82. The company had a trading volume of 630,855 shares, compared to its average volume of 1,156,784. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The firm has a 50 day simple moving average of $8.74 and a two-hundred day simple moving average of $8.77. The stock has a market cap of $316.19 million, a P/E ratio of -1.42 and a beta of 1.80. Emergent BioSolutions Inc. has a 52-week low of $1.82 and a 52-week high of $15.10.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.40. The firm had revenue of $194.70 million during the quarter, compared to analysts' expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter in the prior year, the business earned ($0.77) EPS. Sell-side analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.